Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | AGER | Q15109 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843571 | 0.90 | KDR (0.60) | MEN1KMT2AMAPK1L3MBTL1MAPT | |
| SCHEMBL6839336 | 0.88 | MAPT (0.54) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL6846881 | 0.88 | DRD2 (0.64) | MEN1KMT2AMAPK1MAPTIDO1 | |
| SCHEMBL6843585 | 0.87 | DRD2 (0.54) | MAPK1MAPTALDH1A1IDO1AGER | |
| SCHEMBL6846647 | 0.86 | DRD2 (0.53) | MEN1KMT2AMAPK1MAPTIDO1 | |
| SCHEMBL6843898 | 0.86 | DRD2 (0.53) | KMT2AMAPK1MAPTAGERLMNA | |
| SCHEMBL6844266 | 0.84 | HTR7 (0.57) | MEN1KMT2AMAPTALDH1A1AGER | |
| SCHEMBL6846830 | 0.83 | AGER (0.49) | MEN1KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL6839145 | 0.81 | TDP1 (0.60) | MAPTALDH1A1AGERLMNAHTT | |
| SCHEMBL6843559 | 0.81 | MAPT (0.55) | MEN1KMT2AMAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775118-B1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | claimed |
| US-20040116443-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC | 2004-06-17 | — | — | US | disclosed |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2003-08-21 | — | — | US | disclosed |
| EP-0775118-B1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6548502-B2 | Preventing disorder selected from pathological gambling, attention deficit disorder with hyperactivity disorder, substance addiction such as drug and alcohol and sex in a mammals by administering pyrido(1,2-a) pyrazine derivatives | PFIZER INC | 2003-04-15 | — | — | US | disclosed |
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | PFIZER INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1177792-A2 | Dopamine D4 Ligands for the treatment of novelty-seeking disorders | Pfizer Products Inc. (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5889010-A | PSYCHOLOGICAL DISORDERS; UROGENITAL DISORDERS; COGNITION ACTIVATORS; NERVOUS SYSTEM DISORDERS; VISION DEFECTS; CONGESTIVE HEART FAILURE; DRUG ABRUSE; PARKINSON'S DISEASE;ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | PFIZER INC. (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0775118-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1997-05-28 | — | — | EP | disclosed |
| WO-1996004250-A1 | BENZIMIDAZOLE DERIVATIVES HAVING DOPAMINERGIC ACTIVITY | PFIZER INC. (US) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049209-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | MEN1 4261/4885KMT2A 1418/4885MAPK1 2193/4885 |
| US-20030158208-A1 | Dopamine D4 ligands for the treatment of novelty-seeking disorders | SLC6A3, DRD4, DRD2 | MEN1 4261/4885KMT2A 1418/4885MAPK1 2193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.